

10/522000

15 Rec'd PCT/PTO 18 JAN 2005

Date: January 18, 2005 Label No. EV567259590US I hereby certify that, on the date indicated above, I deposited this paper with identified attachments and/or fee with the U.S. Postal Service and that it was addressed for delivery to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 by "Express Mail Post Office to Addressee" service.

Donald S. Prater  
Name (Print)

Donald S. Prater  
Signature

#2

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:	ENDO et al.	)	Examiner:	Unassigned
		)		
Application No.:	Unassigned	)	Group Art Unit:	Unassigned
		)		
Filed:	January 18, 2005	)	Confirmation No.:	Unassigned
		)		
Docket No.:	3190-071	)	Customer No.:	33432

For: SINGLE CHAIN ANTIBODY AND USE THEREOF

**INFORMATION DISCLOSURE STATEMENT**  
**PURSUANT TO 37 CFR 1.97(b)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

January 18, 2005

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-1449. Pursuant to the current United States Patent and Trademark Office rules, no copies of U.S. Patents/Patent Application Publications are provided.

This Information Disclosure Statement is being submitted before expiration of the three-month period following filing of the above-captioned application.

The above information is presented so that the Patent and Trademark Office can, in the first instance, determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) and 1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents cited in the attached Form PTO-1449 be made of record therein and appear on the first page of any patent to issue therefrom.


Information Disclosure Statement  
U.S. Patent Application No. Unassigned

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in this application and applicant determines that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

It is believed that no fee is required to make this a complete and timely filing. However, if it is determined that a petition or fee is required, the Commissioner is hereby authorized to charge any fee associated with this statement to our Deposit Account No. 50-0925.

Respectfully submitted,

  
Luke A. Kilyk  
Reg. No. 33,251

Atty. Docket No.: 3190-071  
KILYK & BOWERSOX, P.L.L.C.  
53 A East Lee Street  
Warrenton, VA 20186  
Tel.: (540) 428-1701  
Fax: (540) 428-1720  
Enclosures: 7 documents

FORM PTO-1449 (REV. 80)	Atty. Docket No. 3190-071	Application No. Unassigned
<b>INFORMATION DISCLOSURE STATEMENT</b>	APPLICANT: ENDO et al.	
	Filing Date: January 18, 2005	Group Art Unit: Unassigned

**U.S. PATENT DOCUMENTS**

EXAMINER'S INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE, IF APPROPRIATE
	5,723,584	03/03/98	Schatz	530	408	

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
						YES	NO
	WO 95/04069	02/09/95	WIPO	C07H	21/04	yes	

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	Zhang et al., "A Human Monoclonal Antimelanoma Single-Chain Fv Antibody Derived from Tumor-infiltrating Lymphocytes," <i>Cancer Research</i> , Vol. 55, pp. 3584-3591 (1995)
	Luo et al., "Expression of a Fusion Protein of scFv-biotin Mimetic Peptide for Immunoassay," <i>Journal of Biotechnology</i> , Vol. 65, pp. 225-228 (1998)
	Duffy et al., "Site-specific, Enzymatic Biotinylation of Recombinant Proteins in <i>Spodoptera Frugiperda</i> Cells Using Biotin Acceptor Peptides," <i>Analytical Biochemistry</i> , Vol. 262, pp. 122-128 (1998).
	Madin et al., "A Highly Efficient and Robust Cell-Free Protein Synthesis System Prepared from Wheat Embryos: Plants Apparently Contain a Suicide System Directed at Ribosomes," <i>PNAS</i> , Vol. 97, No. 2, pp. 559-564 (2000)
	Ryabova et al., "Functional Antibody Production Using Cell-Free Translation: Effects of Protein Disulfide Isomerase and Chaperones," <i>Nature Biotechnology</i> , Vol. 15, pp. 79-84 (1997)
	Jiang et al., "Expression of Fab Fragment of Catalytic Antibody 6D9 in an <i>Escherichia Coli</i> in Vitro Coupled Transcription/Translation System," <i>FEBS Letters</i> , Vol. 514, pp. 290-294 (2002)

EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.